厄洛替尼致肺癌患者相关性皮疹的临床治疗  

Clinical treatment of Erlotinib treatment-related skin rash in patients with non-small cell lung cancer

作　　者：高文斌[1] 韩传军[2] 张晓晨[2] 刘思思[2] 韩佩妍[2] 

机构地区：[1]大连大学附属中山医院肿瘤科,辽宁大连116001 [2]大连大学

出　　处：《中华肺部疾病杂志（电子版）》2012年第4期15-17,共3页Chinese Journal of Lung Diseases(Electronic Edition)

摘　　要：目的探讨厄洛替尼所致肺癌患者相关性皮疹的特点,及其临床诊疗要点。方法 观察临床确诊的20例非小细胞肺癌(NSCLC)患者口服厄洛替尼后出现的药物相关性皮疹,并进行相应的诊疗,评估皮疹的发生情况以及意义。结果 20例患者不同程度出现1～2级皮疹反应,无3级以上皮疹反应发生,患者耐受性、依从性满意。结论 厄洛替尼相关性皮疹是常见的不良反应,直接干扰了患者的正常治疗,严重影响患者生活质量甚至可导致治疗中断。有效地评估和治疗患者皮疹反应具有积极的意义。Objective To observe the features of Erlotinib treatment-related skin rash and analyze the key points of nursing and treatment. Methods To observe medicine-related skin rash in the 20 patients with non-small cell lung cancer （NSCLC） after they took Erlotinib, to treat accordingly and evaluate its effect and significance. Results Level one to level two of skin rash turned up in the 20 patients, no level three. Endurance and dependence of patient were good. Conclusions Erlotinib-related skin rash is the common adverse effect in patients, it interfere with the normal treatment directly and effect on the quality of life seriously, even leading to the interruption of treatment. Therefore, it is significant that effective assessment and treatment in patients with rash.

关 键 词：支气管肺癌 抗肿瘤药 厄洛替尼 药疹 

分 类 号：R734.2[医药卫生—肿瘤]